How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician criterion.  However, leaving the decision to one single specialist might not be the best. This is when the team’s role becomes essential. 

Cómo suspender la antiagregación previa a una cirugía no cardíaca

This study looked at the advantages consensus decision-making amongst clinicians, surgeons and anesthesiologists to continue or not antiplatelet therapy in patients with second generation drug eluting stents (DES) prior a non-cardiac surgery. 

3582 patients with prior DES stenting receiving non-cardiac surgery were retrospectively included. 3103 patients consulted with the team and follow their recommendation. 

Patients on arbitrarily managed dual antiplatelet therapy (DAPT) before or during surgery presented higher risk of bleeding during surgery and more emergency surgery. These patients were more frequently women and were on DAPT at consultation. 

Arbitrary DAPT decision making nearly doubled the risk of net clinical adverse events  (OR 1.98, CI 95%, 1.98–3.11), tripled cardiovascular events (OR 3.11; CI 95%, 1.31–7.34) and doubled major bleeding (OR 2.34; CI 95%, 1.45–3.76).


Read also: Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.


This association was consistent irrespective of non-cardiac surgery, risk or recommendation on DAPT management. 

Conclusion

DAPT management prior non-cardiac surgery should be decided on a case-by-case basis, and all involved in the procedure should have a say (cardiologist, surgeon, anesthesiologist, etc.). 

The risk of major adverse events have a two and three-fold increase when DAPT management is arbitrary and individually made by a single team member. 

JAHA.120.020079free

Original title: Consensus Decision-Making for the Management of Antiplatelet Therapy before Non-Cardiac Surgery in Patients Who Underwent Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents: A Cohort Study.

Reference: Choongki Kim et al. J Am Heart Assoc. 2021 Apr 20;10(8):e020079. doi: 10.1161/JAHA.120.020079.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...